China Biologic Products (NASDAQ:CBPO) was downgraded by equities research analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating in a note issued to investors on Monday, The Fly reports.
Several other equities research analysts also recently weighed in on the stock. ValuEngine raised shares of China Biologic Products from a “sell” rating to a “hold” rating in a research report on Thursday. BidaskClub raised shares of China Biologic Products from a “strong sell” rating to a “sell” rating in a research report on Thursday. Zacks Investment Research raised shares of China Biologic Products from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 9th. Finally, Credit Suisse Group downgraded shares of China Biologic Products from an “outperform” rating to a “neutral” rating in a research report on Monday, August 6th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $101.00.
Shares of CBPO opened at $69.14 on Monday. The company has a market cap of $2.29 billion, a P/E ratio of 13.97, a PEG ratio of 1.43 and a beta of 1.40. China Biologic Products has a twelve month low of $60.08 and a twelve month high of $107.44.
China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported $0.96 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.09 by ($0.13). The firm had revenue of $119.10 million for the quarter, compared to the consensus estimate of $122.00 million. China Biologic Products had a net margin of 15.50% and a return on equity of 11.44%. China Biologic Products’s revenue was up 19.6% on a year-over-year basis. During the same period last year, the business earned $1.32 EPS. On average, research analysts forecast that China Biologic Products will post 3.71 EPS for the current fiscal year.
A number of hedge funds have recently modified their holdings of CBPO. Bank of America Corp DE boosted its holdings in China Biologic Products by 19.8% in the second quarter. Bank of America Corp DE now owns 651,261 shares of the biopharmaceutical company’s stock worth $64,690,000 after purchasing an additional 107,573 shares during the last quarter. Point72 Hong Kong Ltd purchased a new stake in China Biologic Products in the second quarter worth approximately $10,310,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in China Biologic Products in the second quarter worth approximately $3,906,000. First Trust Advisors LP purchased a new stake in China Biologic Products in the second quarter worth approximately $3,213,000. Finally, Northern Trust Corp boosted its holdings in China Biologic Products by 339.3% in the second quarter. Northern Trust Corp now owns 36,000 shares of the biopharmaceutical company’s stock worth $3,576,000 after purchasing an additional 27,806 shares during the last quarter. Institutional investors own 44.12% of the company’s stock.
About China Biologic Products
China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.
Read More: What are the economic characteristics of a bear market?
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.